Xcout IntelEstrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Subscribe to see Estrella Immunopharma, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Estrella Immunopharma, Inc. at a glance
Estrella Immunopharma, Inc. is a biopharmaceuticals company headquartered in EmeryVille, United States. It is publicly listed (ESLA) with a market capitalisation of $17.8M. Xcout tracks 14 named people at Estrella Immunopharma, Inc., including Cheng Liu (Chief Executive Officer, President & Director).
Estrella Immunopharma, Inc. leadership
- Cheng LiuChief Executive Officer, President & Director
- Jiandong XuChief Financial Officer
- Cheng LiuDirector
- Dengyao JiaDirector
- Fan WuDirector
- Hong ZhangDirector
8 more named people on record for Estrella Immunopharma, Inc., with roles, board committees and tenure — see the full roster →
Estrella Immunopharma, Inc. competitors
A few of Estrella Immunopharma, Inc.'s closest competitors — see the full list of competitors and alternatives →
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company headquartered in South San Francisco, California. It specializes in developing novel T-cell engaging therapies for the treatment of cancer.
BobcatBio, Inc. is a clinical-stage biotechnology company founded in 2020 and headquartered in Hummelstown, Pennsylvania. The company focuses on developing macrophage-based cell therapies and cancer-specific immunotherapies, including its lead cellular therapy candidate RB-1355, for the treatment of solid tumors.
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company located in South San Francisco and Mountain View, California. The company focuses on oncology, leveraging its proprietary Pro-XTEN technology platform to engineer novel protein therapeutics.
ChemoCentryx, Inc. is a biopharmaceutical company with its corporate headquarters and principal place of business located in California.
Artielle Immunotherapeutics is a venture-backed, clinical-stage biotechnology company pioneering novel therapeutics. It maintains its headquarters in Portland, Oregon, with additional presence in San Mateo, California.
Get Estrella Immunopharma, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Estrella Immunopharma, Inc. in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access